Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers

Journal of Clinical Pathology

Volumn 66, Issue 7, 2013, Pages 563-568

  Stumm, Laura ^a   Burkhardt, Lia ^a   Steurer, Stefan ^a   Simon, Ronald ^a   Adam, Meike ^a   Becker, Andreas ^a   Sauter, Guido ^a   Minner, Sarah ^a   Schlomm, Thorsten ^a   Sirma, Hüseyin ^a   Michl, Uwe ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR FOXP2;

ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CANCER RESEARCH; PROSTATE; TUMOUR MARKERS;

ADENOCARCINOMA; AGED; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879421374     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201335     Document Type: Article

References (35)

1. Katoh M. Human FOX gene family (Review). Int J Oncol 2004;25:1495-500.
2. Fox SB, Brown P, Han C, et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 2004;10:3521-7. (Pubitemid 38685462)
3. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
4. Bignone PA, Banham AH. FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther 2008;8:1897-920.
5. Teufel A, Wong EA, Mukhopadhyay M, et al. FoxP4, a novel forkhead transcription factor. Biochim Biophys Acta 2003;1627:147-52. (Pubitemid 36773549)
6. Howarth KD, Blood KA, Ng BL, et al. Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes. Oncogene 2008;27:3345-59. (Pubitemid 351733393)
7. Campbell AJ, Lyne L, Brown PJ, et al. Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. Br J Haematol 2010;149:221-30.
8. Kang C, Drayna D. Genetics of speech and language disorders. Annu Rev Genomics Hum Genet 2011;12:145-64.
9. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. Prostate 2010;71:281-8.
10. Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-60.
11. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-88.
12. Mercer F, Unutmaz D. The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv Exp Med Biol 2009;665:47-59.
13. Lalmansingh AS, Karmakar S, Jin Y, et al. Multiple modes of chromatin remodeling by Forkhead box proteins. Biochim Biophys Acta 2012;1819(7):707-15.
14. Takahashi H, Takahashi K, Liu FC. FOXP genes, neural development, speech and language disorders. Adv Exp Med Biol 2009;665:117-29.
15. Schroeder DI, Myers RM. Multiple transcription start sites for FOXP2 with varying cellular specificities. Gene 2008;413:42-8.
16. Minner S, Kraetzig F, Tachezy M, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011;42:1946-52.
17. Lotan T, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011;17:6563-73.
18. Gravdal K, Halvorsen OJ, Haukaas SA, et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13:7003-11. (Pubitemid 350276881)
19. Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 2007;25:3082-9. (Pubitemid 47218055)
20. Yasui H, Hideshima T, Richardson PG, et al. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006;132:385-97. (Pubitemid 43381614)
21. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
22. Li S, Weidenfeld J, Morrisey EE. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol Cell Biol 2004;24:809-22. (Pubitemid 38057931)
23. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 2009;69:731-4.
24. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
25. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-88. (Pubitemid 351240884)
26. Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-45.
27. Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011;11:507.
28. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-403.
29. Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 2008;68:7541-9.
30. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008;68:7629-37.
31. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009;458:97-101.
32. Markert EK, Mizuno H, Vazquez A, et al. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 2011;108:21276-81.
33. Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell 2010;17:415-16.
34. Yu J, Mani RS, Cao Q, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443 -54.
35. Mochmann LH, Bock J, Ortiz-Tanchez J, et al. Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene 2011;30:2044-56.